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Sepsis and septic shock are characterized by prolonged inﬂammation and delayed resolu-
tion, which are associated with suppression of neutrophil apoptosis.The role of the intrinsic
apoptotic pathway and intracellular factors in regulation of neutrophil apoptosis remain
incompletely understood. We previously reported that the nuclear factor MNDA (myeloid
nuclear differentiation antigen) is fundamental to execution of the constitutive neutrophil
death program. During neutrophil apoptosis MNDA is cleaved by caspases and relocated
to the cytoplasm. However, when challenged with known mediators of sepsis, human
neutrophils of healthy donors or neutrophils from patients with sepsis exhibited impaired
MNDA relocation/cleavage parallel with myeloid cell leukemia-1 (MCL-1) accumulation and
suppression of apoptosis. MNDA knockdown in a model cell line indicated that upon induc-
tion of apoptosis, MNDA promotes proteasomal degradation ofMCL-1, thereby aggravating
mitochondrial dysfunction. Thus, MNDA is central to a novel nucleus-mitochondrion circuit
that promotes progression of apoptosis. Disruption of this circuit contributes to neutrophil
longevity, thereby identifying MNDA as a potential therapeutic target in sepsis and other
inﬂammatory pathologies.
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INTRODUCTION
Different types of hematopoietic cells participate in the inﬂam-
matory response to microbial infection. Among them, circulating
neutrophils are rapidly recruited into infected or injured tissues.
They are the ﬁrst line of defense against pathogens and are key
regulators of the initial response to microbial infection. Effective
removal of neutrophils from inﬂamed tissues is critical for timely
resolution of inﬂammation. However, because of the disruption of
neutrophil programmed cell death in inﬂammatory-related condi-
tions, including sepsis, neutrophils persist in tissues and blood and
portend poor prognosis. Here, we will discuss the recent discov-
ery of a novel nuclear to mitochondrion circuit that is involved
in the control of neutrophil apoptosis and disrupted during
sepsis.
SEPSIS
Sepsis and septic shock (hereafter commonly referred as sepsis)
are portent major medical challenges that result from a harm-
ful host response to infection. Sepsis has a high prevalence and
morbidity. At the beginning of this century, Angus et al. (2001)
reported that, at the time, 9.3% of all cases of death in the USA
was caused by sepsis. The incidence of sepsis was then evaluated as
3 cases per 1000 people, and 2.26 cases per 100 hospital-discharged
patients. The mortality was estimated at 26.6% of all sepsis cases
but, this percentage was signiﬁcantly higher with elderly patients.
The prevalence of this disease is increasing year after year despite
advances in critical care. It is now considered to be the 10th
leading cause of mortality in the United States (Melamed and
Sorvillo, 2009).
Sepsis results from an inappropriate host response to infection.
The initial stage of sepsis is usually considered to result from an
exaggerated or dysregulated inﬂammatory response to infection
(Pene et al., 2012). As sepsis persists, a shift toward immunosup-
pression is observed (Hotchkiss and Nicholson, 2006), concomi-
tant with occurrence of organ failure and secondary infection.
The severity of sepsis is frequently evaluated by various scoring
systems, including the APACHE II (Acute Physiology and Chronic
Health Evaluation II; Knaus et al., 1985) or SAPS II (Simpliﬁed
Acute Physiology Score II; Le Gall et al., 1993) within the ﬁrst
24 h of hospitalization. The score is based on measurements of
vital parameters such as blood pressure, heart rate, respiratory
rate, temperature, neutrophil count, etc. Intriguingly, both high
and low blood neutrophil counts (neutrophilia and neutropenia,
respectively) portend poor prognosis. Despite extensive efforts,
speciﬁc molecular markers for identifying patients with high risk
for sepsis or its more severe form, septic shock, have not been
identiﬁed. Molecular markers with limited accuracy and speci-
ﬁcity have been proposed for deﬁning the stages of the disease.
For instance, the prototypic acute-phase reactant C-reactive pro-
tein can be used as a marker of systemic inﬂammation during
sepsis, whereas high-levels of procalcitonin are detectable at early
stage of bacterial infection (Aalto et al., 2004).
NEUTROPHILS AND SEPSIS
Neutrophils are the ﬁrst line of defense against pathogens.
They generate different proteolytic enzymes as well as reac-
tive oxygen species (ROS) and reactive nitrogen species (RNS)
to destroy invading microorganisms following phagocytosis, or
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extracellulary by neutrophil extracellular trap (NET) formation
(Papayannopoulos et al., 2010; Metzler et al., 2011).
Neutrophils have the shortest life span among leukocytes
and undergo constitutive programmed cell death (apoptosis).
This process is essential for regulation of neutrophil homeosta-
sis. Constitutive apoptosis renders neutrophils unresponsive to
extracellular stimuli and allows their recognition and removal by
macrophages (Savill et al., 2002; Gilroy et al., 2004). This process
is critical for termination of the inﬂammatory response and tissue
repair. Following discharging their function, at the inﬂamma-
tory locus, extravasated neutrophils are though to predominantly
undergo apoptosis. However, signals from the inﬂammatory
milieu can either accelerate or suppress the cell death program,
thereby affecting the fate of neutrophils (Gilroy et al., 2004). Sup-
pressed neutrophil apoptosis is often detected in patients with
inﬂammatory pathologies, including sepsis and septic shock and
portends poor prognosis (Keel et al., 1997; Matute-Bello et al.,
1997; Taneja et al., 2004). Exposure of neutrophils to inﬂammatory
mediators such asGM-CSF, IL-8 or to bacterial constituents results
in delayed apoptosis (El Kebir and Filep, 2010; Geering and Simon,
2011). Preserving neutrophil activities at the sites of infection may
be required for complete elimination of invading pathogens, but
could also aggravate injury to the host, resulting in persistent tissue
damage. Therefore, the regulation of neutrophil apoptosis is criti-
cal to control the balance between their antimicrobial effectiveness
and potential deleterious effect on tissues.
Signaling pathways promoting survival of neutrophils during
sepsis are converging to control expression and degradation of
key factors inﬂuencing the programmed cell death. In mature
neutrophils, the anti-apoptotic protein myeloid cell leukemia-1
(MCL-1) and the pro-apoptotic protein Bcl2-associated X (BAX)
are critical for the regulation of mitochondrial transmembrane
potential (ΔΨm), and hence, activation of effector caspases (El
Kebir and Filep, 2010; Geering and Simon, 2011; Milot and
Filep, 2011). Since the control of mitochondrial transmembrane
potential is central to the intrinsic apoptotic pathway, these dis-
coveries placed forth the intrinsic apoptotic pathway in regulation
of neutrophil apoptosis.
INTRINSIC APOPTOSIS PATHWAY AND MCL-1 IN
NEUTROPHILS
MCL-1 is an anti-apoptotic factor of theBcl-2 family. MCL-1 accu-
mulation protects against formation of the BAK-BAXheterodimer
on the external mitochondrial membrane and subsequent release
of cytochrome c along with other molecules inﬂuencing apop-
tosis like SMAC/Diablo, endonuclease G, and AIF (apoptosis-
inducing factor), from themitochondrial innermembrane. Hence,
MCL-1 protects ΔΨm and thus regulates the internal apoptotic
pathway.
Unlike other members of the Bcl-2 family, MCL-1 protein has
a short half-life and its levels of expression change substantially
as neutrophils age and upon exposure of neutrophils to inﬂam-
matory mediators (Moulding et al., 2001; Craig, 2002). Indeed,
MCL-1 protein expression inversely correlates with the degree
of neutrophil apoptosis in both experimental models and clini-
cal settings. Rapid loss in MCL-1 corresponds to development of
apoptosis and MCL-1 knockdown results in dramatic decreases
in the neutrophil lifespan (Moulding et al., 1998; Dzhagalov et al.,
2007). Modiﬁcation inMcl-1 transcription accounts formost vari-
ation of MCL-1 expression observed upon stress conditions (Dong
et al., 2011). At the transcription level, Mcl-1 is regulated by dif-
ferent transcription factors including MYC, NF-κB (RelA/p65),
STAT5, and HIF-1α (Akgul et al., 2000; Negrotto et al., 2006; Bev-
erly and Varmus, 2009; Thomas et al., 2010). RNA processing
and protein accumulation/turnover are also important for reg-
ulation of MCL-1 expression (Bae et al., 2000). The turnover of
MCL-1 results primarily from the proteasome activity (Zhong
et al., 2005). MULE/Arf-BP1, an E3 ubiquitin ligase, ubiquitinates
MCL-1 and subsequently enhances its proteasomal degradation
(Zhong et al., 2005). This activity can be counterbalanced by the
activity of the deubiquitinase USP9X which was demonstrated to
deubiquitinate and thereby, to stabilize MCL-1 (Schwickart et al.,
2010). However, surprisingly little is known about regulation of
MCL-1.Wehave identiﬁedmyeloid nuclear differentiation antigen
(MNDA) as a regulator of the proteasomal degradation of MCL-1
(Fotouhi-Ardakani et al., 2010 and see below).
ROLE OF MITOCHONDRIA IN NEUTROPHIL APOPTOSIS
In neutrophils, mitochondria have an atypical function and their
role seems to be restricted to apoptosis (van Raam and Kuijpers,
2009). This view has been nourished by the observation that neu-
trophils rely on glycolysis for energy formation and even for a
long time mitochondria could not be detected in these cells. The
electron transport chain is inefﬁcient to transport electrons from
complexes III to IV in neutrophils (van Raam et al., 2008). How-
ever, it is not to say that it exerts no activity in neutrophils since,
inhibitors of the mitochondrial respiratory chain complex I can
modulate the severity of lung injury evoked by LPS (Zmijewski
et al., 2009). Enhanced production of H2O2 by neutrophils results
in inhibition of IκB-α degradation hence preventing the activa-
tion of NF-κB, a key regulator of inﬂammatory gene expression
in neutrophils (Zmijewski et al., 2008). Thus, the mitochon-
drial respiratory chain appears to be only partially active in
neutrophils.
MNDA: A KEY COMPONENT OF A NOVEL NUCLEUS TO
MITOCHONDRION CIRCUIT
Different factors exerting their activity in the nucleus have been
reported to participate in and inﬂuence the internal apoptosis
pathway. While some nuclear proteins including E2F1, STAT3,
HIF-1α, and NF-κB are well known to regulate expression of genes
encoding pro- or anti-apoptotic factors, other nuclear proteins
like MNDA, p53, p21/WAF1, proliferating cell nuclear antigen
(PCNA), nur77, SHP, and possibly p73, have been reported or
proposed to act as nuclear signals (transducers) to inﬂuence
the intrinsic apoptotic pathway upon relocation or speciﬁc cyto-
plasmic accumulation (Chipuk et al., 2003; Dumont et al., 2003;
Mihara et al., 2003; Wang, 2005; Fotouhi-Ardakani et al., 2010;
Witko-Sarsat et al., 2010; Milot and Filep, 2011). Some of these
factors have been reported to directly affect pro- or anti-apoptotic
factors and hence, apoptosis. MNDA is one of them.
Myeloid nuclear differentiation antigen is a human hematopoi-
etic speciﬁc factor of the HIN-200 family. This family of factors is
composed of the functionally related proteins IFI16, AIM2, IFIX,
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and MNDA (Choubey and Panchanathan, 2008). MNDA localizes
predominantly to the nucleus and is expressed mainly in myeloid
cells. It has been suggested that MNDA may function as a master
regulator of monocytic and granulocytic lineages (Novershtern
et al., 2011). Recently, MNDA has been proposed to be a tran-
scription factor (Suzuki et al., 2012). Like other members of the
HIN-200 family, MNDA contains a pyrin/PAAD/DAPIN domain
that mediates binding between proteins involved in apoptotic
and inﬂammatory signaling pathways (Fairbrother et al., 2001).
It also contains a HIN-200 domain, which is thought to promote
protein–protein (Dawson and Trapani, 1996; Choubey and Pan-
chanathan, 2008) and protein–DNA interactions (Jin et al., 2012).
MNDA gene regulation is inﬂuenced by interferons (Choubey and
Panchanathan, 2008). MNDA was initially proposed to regulate
myeloid cell differentiation as well as development of sporadic
myelodysplastic syndrome (Briggs et al., 2006).
The potential implication of MNDA in regulation of apoptosis
in myeloid cells and in inﬂammation has been directly assessed
in neutrophil granulocytes (Fotouhi-Ardakani et al., 2010). In
bone marrow-derived and mature neutrophils, MNDA is pre-
dominantly located in the nucleus. In neutrophils undergoing
apoptosis, MNDA is cleaved by caspases, presumably caspase-3,
and relocated to the cytoplasm. However, the cleavage of MNDA is
likely not required for its cytoplasmic accumulation since the full-
length MNDA could also be detected in the cytoplasm. Culture
of human neutrophils with inﬂammatory mediators, like bacterial
constituents and platelet-activating factor, promotes their survival
and indicates a clear correlation between the degree of neutrophil
apoptosis and MNDA cleavage as well as cytoplasmic accumu-
lation. These ﬁndings suggest that MNDA could participate in
regulation of apoptosis in neutrophils.
A causal relationship between MNDA and apoptosis has been
established in a model cell line, the promyelocytic leukemia cell
lineHL-60,which expresses endogenousMNDA(Duhl et al., 1989;
Savli et al., 2002). We created two MNDA-deﬁcient HL-60 cell
lines by the stable genomic integration of vectors encoding spe-
ciﬁc small hairpin RNA (shRNA). In these engineered model cell
lines, knockdownof MNDApartially protectedHL-60 cells against
genotoxic stress-induced apoptosis, markedly attenuated activa-
tion of caspase-3, but not caspase-8, and prevented mitochondrial
dysfunction (Fotouhi-Ardakani et al., 2010). These observations
identify MNDA as a modulator of the intrinsic (mitochondrial)
pathway of apoptosis.
The importance of the anti-apoptotic factor MCL-1 in con-
trol of ΔΨm and neutrophil apoptosis (Moulding et al., 1998;
Dzhagalov et al., 2007) led us to interrogate whether MNDA
could inﬂuence the internal pathway of apoptosis via MCL-1.
Interestingly, we found that: (i) MNDA co-immunoprecipitates
with MCL-1; and (ii) after induction of apoptosis, MCL-1 accu-
mulation was greatly enhanced in MNDA-deﬁcient HL-60 cells
compared to MNDA proﬁcient HL-60 cells (Fotouhi-Ardakani
et al., 2010). Similar results were obtained in the presence of
the protein synthesis inhibitor cycloheximide, suggesting that
MNDA inﬂuences the turnover of MCL-1 protein. Since MCL-1
turnover is mainly regulated by proteasomal degradation (Zhong
et al., 2005), we blocked the proteasome activity with MG132
and found that under such condition, MNDA failed to affect
MCL-1 accumulation. These ﬁndings conﬁrm that the rapid fall in
MCL-1 expression is due to proteasomal degradation and indicate
that, when present, MNDA promotes proteasomal degradation
of MCL-1. By contrast, MNDA knockdown slowed down MCL-1
turnover and rendered HL-60 cells resistant to genotoxic stress-
induced apoptosis, indicating that MNDA regulation of MCL-1
degradation is required for the execution of the constitutive cell
death program. Collectively these ﬁndings indicate that cytoplas-
mic accumulation of MNDA is not merely a consequence, but
rather an important mechanism promoting apoptosis in HL-60
cells and likely, in mature human neutrophils (Figure 1).
It is not known whether co-immunoprecipitation of MNDA
and MCL-1 resulted from direct protein–protein interaction or
which region(s) of MNDA is(are) required for this association.
However, the MNDA PAAD/DAPIN/Pyrin domain, which is
common todifferent proteins involved in apoptosis and inﬂamma-
tion, and/or the HIN-200 domain that mediates protein–protein
interactions (Asefa et al., 2004) could be critical for the MNDA
interactionwithMCL-1. Indeed, the PAAD/DAPIN/Pyrin domain
was shown to promote self-association of MNDA (Xie et al., 1997),
and might also mediate association with other proteins. For
instance, IFI16, which contains a PAAD/DAPIN/Pyrin domain,
interacts with p53, thereby modulating senescence and apoptosis
(Song et al., 2008). In mice, members of the HIN-200 family were
shown to promote inﬂammation through interacting with NF-κB
(Min et al., 1996). These results demonstrate that a member of
the HIN-200 family or a protein with the PAAD/DAPIN/Pyrin
domain co-immunoprecipitates with an anti-apoptotic protein of
the Bcl-2 family to regulate apoptosis. It remains to be investigated
whether this mechanism is common to all MNDA expressing cells
including hematopoietic progenitors (Briggs et al., 2006).
ROLE FOR MNDA DURING SEPSIS
It is well established that neutrophils isolated from the peripheral
blood of healthy volunteers undergo apoptosis when cultured for
24–48 h in vitro. By contrast, under the same conditions of culture,
neutrophils of patients with sepsis exhibit markedly prolonged
survival due to suppressed apoptosis (Keel et al., 1997; Matute-
Bello et al., 1997; Fotouhi-Ardakani et al., 2010; Paunel-Gorgulu
et al., 2012). The enhanced neutrophil longevity is associated with
preserved ΔΨm and inversely correlates with cytoplasmic accu-
mulation of MNDA (Fotouhi-Ardakani et al., 2010). As predicted
from the comprehensive study on MNDA in model cell lines (see
above), during neutrophil apoptosis MNDA is relocated from
the nucleus to the cytoplasm whereby it directly interacts with
MCL-1 and promotes its proteasomal degradation (Figure 1).
Although the signaling pathways involved in these events have
not been elucidated, MNDA remains sequestered in the nucleus of
neutrophils of patients in sepsis (Fotouhi-Ardakani et al., 2010).
Consistently, culture of neutrophils from healthy volunteers with
LPS, bacterial DNA, or platelet-activating factor partially repli-
cated the abnormalities seen in the clinical samples, including
the sequestration of MNDA to the nucleus (Fotouhi-Ardakani
et al., 2010). Most interestingly, similar results were obtained
when neutrophils of healthy donors were cultured in presence of
serum from sepsis patient (Fotouhi-Ardakani et al., 2010). These
ﬁndings suggest that neutrophils integrate yet unidentiﬁed cues
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FIGURE 1 | Proposedmodel for MNDA regulation of neutrophil apoptosis.
Cytoplasmic relocation and cleavage of MNDA results in aggravation of
mitochondrial dysfunction through promotion of proteasomal degradation of
MCL-1. Activation of this novel nucleus-mitochondrion circuit would then
accelerate execution of the apoptotic death program. Conversely, prevention
of MNDA relocation and cleavage would prolong neutrophil survival by
retarding apoptosis. The mechanisms by which bacterial components and/or
inﬂammatory modulators could negatively inﬂuence MNDA relocation and
cleavage and hence, interfere with this nuclear-mitochondrial circuit remains
to be deﬁned. Broken line indicates yet undeﬁned mechanism.
from the inﬂammatory milieu, which would prevent the cytoplas-
mic relocation and/or accumulation of MNDA, events that favor
neutrophil apoptosis. Although our pilot clinical study was not
powered to assess outcome, we noted that patients who had died
exhibited markedly suppressed neutrophil apoptosis with mini-
mal or complete absence of MNDA translocation and/or cleavage
in neutrophils. Suppressed apoptosis in circulating neutrophils
may contribute to neutrophilia, which predicts a poor prognosis,
whereas delayed apoptosis in emigrated or trapped neutrophils
contributes to aggravation of tissue injury, in particular damage to
the airways (Matute-Bello et al., 1997; Hotchkiss and Nicholson,
2006). Apoptotic neutrophils sequester cytokines during endo-
toxin shock in mice (Ren et al., 2008) and thus may contribute to
resolution of sepsis. Conversely, failure of neutrophils to undergo
timely apoptosis would likely impair this pro-resolution effect.
Clearly, additional studies are required to assess the precise role of
MNDA in facilitating resolution of inﬂammation.
In conclusion, cytoplasmic accumulation of MNDA plays
an important role in the progression of apoptosis. This repre-
sents a novel mechanism whereby MNDA, which predominantly
localizes to the nucleus, regulate MCL-1 degradation and conse-
quently mitochondrial function following its accumulation in the
cytoplasm. The investigation of MNDA in neutrophils demon-
strates that prevention of cytoplasmic MNDA accumulation likely
contributes to suppressed apoptosis of neutrophils in patients
with sepsis. Therefore, targeting MNDA may have a therapeu-
tic potential for the treatment of sepsis and other inﬂammatory
disorders.
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